Estrogen and Parkinson's disease

Area of Science:

• Neurobiology
• Endocrinology
• Movement Disorders

Background:

• Estrogen exerts biochemical and behavioral effects on the dopaminergic system.
• These effects can be neuroprotective, modulating insults to dopamine circuitry, or symptomatic, with documented suppressive and enhancing actions.
• The mesostriatal dopaminergic system is a key target for estrogen's influence.

Purpose of the Study:

• To review the neuroprotective and symptomatic effects of estrogen on the dopaminergic system.
• To examine the influence of estrogen on Parkinson's disease (PD) prevalence, progression, and symptoms.
• To inform therapeutic strategies for women with PD and related movement disorders.

Main Methods:

• Review of pre-clinical literature on estrogen's effects on the mesostriatal dopaminergic system.
• Analysis of studies investigating estrogen's impact on Parkinson's disease.
• Synthesis of findings related to symptomatic and neuroprotective actions of estrogen.

Main Results:

• Estrogen demonstrates both neuroprotective and symptomatic (suppressive/enhancing) effects on the dopaminergic system.
• Evidence suggests estrogen influences Parkinson's disease prevalence, progression, and clinical presentation.
• Hormonal fluctuations impact disease symptoms and medication response in women.

Conclusions:

• Understanding estrogen's modulation of the dopaminergic system is crucial for treating women with Parkinson's disease.
• Tailoring therapies based on estrogen's role can optimize treatment for menstrual symptom fluctuations.
• Guidance for hormone replacement therapy in women with Parkinson's disease or at genetic risk can be developed.